urodilatin
Small moleculeexperimental
Urodilatin (URO) is a hormone that causes natriuresis by increasing renal blood flow. It is secreted in response to increased mean arterial pressure and increased blood volume from the cells of the distal tubule and collecting duct. It is important in oliguric patients as it lowers serum creatinine and increases urine output. — Wikipedia
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2003 (NCT00390624)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
NPR1 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaUrodilatin ↗
Also known as
- anf (95-126)
- anp (95-126)
- atrial natriuretic factor prohormone (95-126)
- atrial natriuretic peptide (95-126)
- atriopeptin (95-126)
- ularitide
- urodilatin
- urodilatin
- urodilatin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04311489 | Phase 2 | Jun 1, 2020 | Aarhus University, ADS AIPHIA Development Services AG |
| NCT00390624 | Phase 2 | Jul 1, 2003 | Rocky Mountain Cancer Centers, University of Colorado, Denver, Yale University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| ADS AIPHIA Development Services AG | For profit | 1 | 0 | 1 | 2020 |
| Rocky Mountain Cancer Centers | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2003 |
5 organizations
Page 1 / 1